Carmat Total Artificial Heart Early Feasibility Study
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 发起方
- 入组人数
- 10
- 试验地点
- 8
- 主要终点
- Survival
研究概览
简要总结
Feasibility study of the Carmat TAH as a treatment for transplant-eligible patients in severe, end-stage heart failure.
详细描述
This is a prospective, multi-center, staged feasibility study designed to assess the initial evidence of safety and performance of the Carmat TAH in the treatment of severe, end-stage heart failure. This study will include up to 7 centers in the US. The study population will include up to 10 transplant-eligible patients enrolled and implanted with the Carmat TAH.
Data collection will be recorded prior to implantation of the device and for six months following implant, then long term at 9, 12, 18 and 24 months while the patient remains on the device. Adverse events, as defined by INTERMACS, while on device support will be collected throughout the study until study closure and will be adjudicated by an independent Clinical Event Committee.
Progress reports of the clinical outcomes will be reviewed by the DSMB after implantation of each patient and every three months thereafter while any patient is supported with the device. A progress report will be sent to FDA for review after three subjects have been implanted and followed for 60 days.
The primary objective of the study is survival on an original Carmat device at 180 days post-implant or survival to cardiac transplantation if occurring before 180 days post-implant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be 18 years of age or older at the time of informed consent
- •Anatomic compatibility confirmed using 3D imaging (CT-scan).
- •Inotrope dependent (with documented attempt to wean) or cardiac Index (CI) < 2.2 L/min/m2 if inotropes are contra-indicated (heart failure due to restrictive or constrictive physiology).
- •On Optimal Medical Management as judged by the investigator based on current Heart Failure practice guidelines (ESC/AHA).
- •Eligible for biventricular Mechanical Circulatory Support according to ISHLT guidelines for mechanical circulatory support:
- •Biventricular failure with at least two of the following hemodynamic/ echocardiographic measurements implying right heart failure: RVEF ≤30%; RVSWI ≤0.25mmHg*L/m2; TAPSE ≤14mm; RV-to-LV end-diastolic diameter ratio >0.72; CVP >15 mmHg; CVP-to-PCWP ratio >0.63; Tricuspid insufficiency grade 4; PAPi<2
- •Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate.
- •Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease).
- •Patient has signed the informed consent, has full understanding of procedures, and is committed to following study requirements.
- •Eligible for cardiac transplantation
排除标准
- •Known intolerance to anticoagulant or antiplatelet therapies or known Heparin Induced Thrombocytopenia.
- •Presence of any non-temporary mechanical circulatory support
- •Presence of temporary mechanical circulatory support such as Impella (all types) or IABP with a duration greater than 21 days
- •Presence of ECMO with a duration greater than 7 days
- •Patient is intubated and unconscious, or intubated and not awake
- •Coagulopathy defined by platelets < 100k/µl or INR ≥ 1.5 not due to anticoagulant therapy.
- •Cerebrovascular accident < 3 months or symptomatic or a known > 80% carotid stenosis.
- •Known abdominal or thoracic aortic aneurysm > 5 cm that has not been treated.
- •Severe end-organ dysfunction as per any of the following criteria:
- •Total bilirubin > 2.5 mg/dl or cirrhosis evidenced by ultrasound, CT-scan and positive biopsy
- •eGFR < 30ml/min/1.73m2 or the need for chronic renal replacement therapy
- •History of severe Chronic Obstructive Pulmonary Disease with FEV1/FVC <0.7, or FEV1<50% predicted or severe restrictive lung disease.
- •Recent blood stream infection (<7 days).
- •Documented amyloid light-chain (AL amyloidosis).
- •Hemodynamically significant peripheral vascular disease with documented ankle- brachial pressure index (ABPI) <0.
- •Illness, other than heart disease, that would limit survival to less than 2 years.
- •Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely to impair compliance with the study protocol and TAH management that in the opinion of the investigator could interfere with the ability to manage the therapy (i.e. non-compliance to heart failure therapy, uncontrolled diabetes, mental health issue, etc.).
- •Current or planned pregnancy or breast feeding (woman of childbearing age will have to show negative pregnancy test).
- •Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound the study results or affect the study.
结局指标
主要结局
Survival
时间窗: 180 days
Proportion of patients surviving on the Carmat TAH
次要结局
- Adverse Events(180 days)
- Hospital readmission rate(180 days)
- Survival without Permanent Neurologic Deficit(180 days)
- Change in functional status(180 days)
- Post transplant survival(30 days)
- Change in functional status measured by the Six Minutes Walk Test(180 days)
- Generic health status change(180 days)